If LOXO-101 (Larotrectinib) gets FDA approval, then this will be the second cancer treatment medicine produced by biomarker identification technique. The first was Keytruda manufactured by Merck Company. LOXO-101 is used to detect tumor cells caused by genetic disorder in any part of the human body. The final decision by the FDA will be made in late November 2018.

On Tuesday, August 7th 2018, from 8 a.m. to 4 p.m. at the Auditorium Room, 7th floor KX Tower (Knowledge Exchange), on Krung Thon Buri Road, Bangkok, the Department of Business Development under the Ministry of Commerce sets up an exhibition of the Biz Space Startup Solutions for SME or so-called the 3rd networking and supporting event for Start Up and SME businesses which was an Innovation Driven Enterprise (IDE) project in 2018.